CHC Healthcare Group
TWSE:4164
Intrinsic Value
CHC Healthcare Group engages in investment and the distribution, maintenance, and lease of radiation oncology, neuromedicine, imaging medicine, ophthalmology, and surgical instruments. [ Read More ]
The intrinsic value of one CHC Healthcare Group stock under the Base Case scenario is 77.27 TWD. Compared to the current market price of 52.4 TWD, CHC Healthcare Group is Undervalued by 32%.
Valuation Backtest
CHC Healthcare Group
Run backtest to discover the historical profit from buying and selling CHC Healthcare Group stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
CHC Healthcare Group
Current Assets | 4.4B |
Cash & Short-Term Investments | 2.2B |
Receivables | 963.4m |
Other Current Assets | 1.3B |
Non-Current Assets | 9.3B |
Long-Term Investments | 1.9B |
PP&E | 6.1B |
Intangibles | 625.4m |
Other Non-Current Assets | 743.8m |
Current Liabilities | 1.9B |
Accounts Payable | 341.3m |
Short-Term Debt | 582.8m |
Other Current Liabilities | 953.1m |
Non-Current Liabilities | 5.7B |
Long-Term Debt | 4.6B |
Other Non-Current Liabilities | 1.2B |
Earnings Waterfall
CHC Healthcare Group
Revenue
|
3.7B
TWD
|
Cost of Revenue
|
-2.7B
TWD
|
Gross Profit
|
984.8m
TWD
|
Operating Expenses
|
-467.8m
TWD
|
Operating Income
|
517m
TWD
|
Other Expenses
|
-175.1m
TWD
|
Net Income
|
341.9m
TWD
|
Free Cash Flow Analysis
CHC Healthcare Group
Profitability Score
Profitability Due Diligence
CHC Healthcare Group's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
Score
CHC Healthcare Group's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
CHC Healthcare Group's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Score
CHC Healthcare Group's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
CHC Healthcare Group
According to Wall Street analysts, the average 1-year price target for CHC Healthcare Group is 70.38 TWD with a low forecast of 69.69 TWD and a high forecast of 72.45 TWD.
Shareholder Return
Price
CHC Healthcare Group
Average Annual Return | 8.25% |
Standard Deviation of Annual Returns | 9.55% |
Max Drawdown | -45% |
Market Capitalization | 8.7B TWD |
Shares Outstanding | 166 419 008 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
CHC Healthcare Group engages in investment and the distribution, maintenance, and lease of radiation oncology, neuromedicine, imaging medicine, ophthalmology, and surgical instruments. The company is headquartered in Taipei City, Taipei. The company went IPO on 2011-10-18. The firm primarily involves in the agent distribution of radiation oncology, neurology, medical image and nuclear medical, as well as dental and ophthalmological equipment and instrument. The firm also offers related maintenance and leasing services, components and consumable materials and specialty consulting services. The firm deals with medical instrument with brands as Elekta, PTW, GE, Ashland, Megin, Leica, Hillrom, Sony, Ellex and Wexler, among others. The firm is also involved in the operation of pharmacy.
Contact
IPO
Employees
Officers
The intrinsic value of one CHC Healthcare Group stock under the Base Case scenario is 77.27 TWD.
Compared to the current market price of 52.4 TWD, CHC Healthcare Group is Undervalued by 32%.